Background: The ability to cross and treat a CTO is still challenging and difficult, the efficacy and safety for CTO has limited data. Therefore, We evaluated the effectiveness and safety of DES for CTO. Methods: We assessed our data from consecutive 89 patients (96cases) with CTO who underwent PCI with Sirolimus(n=56) or Paclitaxel(n=33) eluting stents from March 2003 to June 2005. The primary end points of this study were late luminal loss at 6months and major adverse cardiovascular events(death, nonfatal MI, TVR) at 12months. Results: The baseline clinical and angiographic characteristics were similar between two groups. There were no differences in the angiographic in-stent late loss and binary restenosis between two groups. However, the in-segment LL was significantly lower in the SES group than the PES group(see table 1.). At one-year follow up, the MACE-free survival rate was significantly higher in the SES group(90.2% vs. 82.4%; p=0.006). Conclusion: Both SES and PES are safe and effective in patients with CTO. However, SES group showed more favorable clinical outcomes compared with PES group.